Gene · 2115
Papers2,342
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
521 to 540 of 2,342
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. | Clin Cancer Res | 2022 | 35110417 | PubTator, text mining | PubMed |
| Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress. | Stem Cell Res Ther | 2022 | 35093187 | PubTator, text mining | PubMed |
| Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors. | Proc Natl Acad Sci U S A | 2022 | 35091470 | PubTator, text mining | PubMed |
| Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. | Prostate | 2022 | 35084050 | PubTator, text mining | PubMed |
| Cryopreservation and post-thaw characterization of dissociated human islet cells. | PLoS One | 2022 | 35081145 | PubTator, text mining | PubMed |
| Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment. | Curr Oncol Rep | 2022 | 35059992 | PubTator, text mining | PubMed |
| Multiple ETS Factors Participate in the Transcriptional Control of TERT Mutant Promoter in Thyroid Cancers. | Cancers (Basel) | 2022 | 35053525 | PubTator, text mining | PubMed |
| Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. | JCI Insight | 2022 | 35050902 | PubTator, text mining | PubMed |
| Systematic analysis of naturally occurring insertions and deletions that alter transcription factor spacing identifies tolerant and sensitive transcription factor pairs. | Elife | 2022 | 35049498 | PubTator, text mining | PubMed |
| Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. | J Clin Oncol | 2022 | 35041493 | PubTator, text mining | PubMed |
| ETS factors in prostate cancer. | Cancer Lett | 2022 | 35033589 | PubTator, text mining | PubMed |
| N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1. | Cancer Lett | 2022 | 35032557 | PubTator, text mining | PubMed |
| Fibrinogen-like protein 2 in gastrointestinal stromal tumour. | J Cell Mol Med | 2022 | 35029030 | PubTator, text mining | PubMed |
| Validation and clinical application of transactivation assays for RUNX1 variant classification. | Blood Adv | 2022 | 35026845 | PubTator, text mining | PubMed |
| Histone demethylase JMJD1A in cancer progression and therapeutic resistance. | Mol Carcinog | 2022 | 35020958 | PubTator, text mining | PubMed |
| Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. | Nat Commun | 2022 | 35013146 | PubTator, text mining | PubMed |
| Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition. | Prostate | 2022 | 34994974 | PubTator, text mining | PubMed |
| Beyond Prostate Specific Antigen: New Prostate Cancer Screening Options. | World J Mens Health | 2022 | 34983086 | PubTator, text mining | PubMed |
| Deciphering the Polygenic Basis of Racial Disparities in Prostate Cancer By an Integrative Analysis of Genomic and Transcriptomic Data. | Cancer Prev Res (Phila) | 2022 | 34965922 | PubTator, text mining | PubMed |
| Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review). | Int J Oncol | 2022 | 34958107 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2115/papers?page=27